当前位置: X-MOL 学术Bioorg. Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Several non-salt and solid thienopyridine derivatives as oral P2Y12 receptor inhibitors with good stability
Bioorganic & Medicinal Chemistry Letters ( IF 2.5 ) Pub Date : 2022-09-01 , DOI: 10.1016/j.bmcl.2022.128969
Lei Liu 1 , Lingjun Li 1 , Jing Yuan 1 , Wei Liu 1 , Yuquan Li 1 , Shijun Zhang 1 , Changjiang Huang 1
Affiliation  

A series of novel thienopyridine derivatives were designed and synthesized as P2Y12 receptor inhibitors. Several solid compounds were assessed for inhibitory effect where they exhibited stronger potency than clopidogrel. Compound 6b and 6g were evaluated for metabolism to verify that they could overcome clopidogrel resistance and for toxicity where they showed lower toxicity than prasugrel. Compound 6b exhibited lower risk of bleeding than prasugrel and showed good stability under stress testing. Overall, as a promising antiplatelet agent, representative compound 6b showed the following advantages: (1) no drug resistance for CYP2C19 poor metabolizers; (2) higher potency than clopidogrel; (3) lower toxicity than prasugrel; (4) lower risk of bleeding than prasugrel; (5) good stability as a non-salt solid.



中文翻译:

几种非盐和固体噻吩并吡啶衍生物作为口服 P2Y12 受体抑制剂,具有良好的稳定性

设计并合成了一系列新型噻吩并吡啶衍生物作为P2Y 12受体抑制剂。评估了几种固体化合物的抑制作用,它们表现出比氯吡格雷更强的效力。对化合物6b6g的代谢进行了评估,以验证它们可以克服氯吡格雷抗性和毒性,其中它们显示出比普拉格雷更低的毒性。与普拉格雷相比,化合物6b表现出较低的出血风险,并且在压力测试下表现出良好的稳定性。总体而言,作为一种有前途的抗血小板药物,代表化合物6b表现出以下优点:(1)对CYP2C19弱代谢者无耐药性;(2) 比氯吡格雷效力更高;(3) 毒性低于普拉格雷;(4) 出血风险低于普拉格雷;(5)作为非盐固体具有良好的稳定性。

更新日期:2022-09-01
down
wechat
bug